سعر ميزوسيبت 50/5مجم امبول للحقن عضل 2024

Monthly combined injectable contraceptive: oily solution of norethisterone enantate 50 mg and estradiol valerate 5 mg per 1 ml ampoule for intramuscular injection.

• Contraception in women.Population: Women after menarcheWHO Prequalification of Medicines

• Common: changes in menstrual bleeding pattern (including amenorrhoea and dysmenorrhoea), weight change, headache, nausea, abdominal pain, mood swings/depression, fluid retention/oedema, acne and breast pain.International label, same formulation · WHO Prequalification of Medicines
• Rare but serious: venous and arterial thromboembolism.International label, same formulation · WHO Prequalification of Medicines

• Presence or history of venous thromboembolism (DVT/PE), predisposition to VTE, major surgery with prolonged immobilisation, or multiple VTE risk factors.International label, same formulation · WHO Prequalification of Medicines
• Presence or history of arterial thromboembolism (e.g., myocardial infarction, angina, stroke or TIA), migraine with aura, or high arterial risk (diabetes with vascular symptoms, severe hypertension, severe dyslipoproteinaemia).International label, same formulation · WHO Prequalification of Medicines
• Concomitant use with ombitasvir/paritaprevir/ritonavir with or without dasabuvir, glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir.International label, same formulation · WHO Prequalification of Medicines

• Combined hormonal contraceptives increase the risk of venous and arterial thromboembolism; assess individual risk factors before use.International label, same formulation · WHO Prequalification of Medicines
• Discontinue if migraine occurs for the first time or worsens, if visual disturbances or signs of thrombosis appear, and 4 weeks before elective surgery or prolonged immobilisation.International label, same formulation · WHO Prequalification of Medicines
• Pulmonary oil microembolism (cough, dyspnoea, chest pain, vasovagal reactions) can occur with oily injections; inject very slowly.International label, same formulation · WHO Prequalification of Medicines

• Enzyme inducers (e.g., rifampicin, rifabutin, griseofulvin, St John's wort, nevirapine, ritonavir, nelfinavir)May reduce contraceptive effectiveness; use a barrier method during treatment and for 28 days afterwards.WHO Prequalification of Medicines
• Strong/moderate CYP3A4 inhibitors (e.g., azole antifungals, macrolides) and etoricoxibMay increase plasma concentrations of the estrogen and/or progestogen.WHO Prequalification of Medicines
• Hepatitis C regimens (ombitasvir/paritaprevir/ritonavir ± dasabuvir; glecaprevir/pibrentasvir; sofosbuvir/velpatasvir/voxilaprevir)Contraindicated (ALT elevation risk); switch to another contraceptive method and restart about 2 weeks after completing the regimen.WHO Prequalification of Medicines

• Not indicated during pregnancy; exclude pregnancy before the first injection and discontinue if pregnancy occurs. Inadvertent use in early pregnancy has not shown an increased risk of birth defects.International label, same formulation · WHO Prequalification of Medicines
• Should not be started within 6 weeks after delivery in breastfeeding women; may reduce milk quantity and small amounts of hormones pass into milk.International label, same formulation · WHO Prequalification of Medicines

English text not available for this section.